Angioedema refers to the swelling of the lower layers of skin and mucous membranes. It can affect any part of the body including the face, hands, feet, genitals, or intestinal tract. The common causes of angioedema include hereditary angioedema (HAE), medications such as ACE inhibitors, allergic reactions to foods, insect bites and stings. Treatment of angioedema involves the use of drugs such as C1 esterase inhibitors, bradykinin receptor antagonists, antihistamines, glucocorticoids and epinephrine.

The Global Angioedema Treatment Market is estimated to be valued at US$ 470.4 Mn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the Angioedema Treatment are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd. Bayer AG dominates the market with its portfolio of drugs such as Berinert and Cinryze approved for treatment of HAE.

The key opportunities in the angioedema treatment market include rise in approvals of novel drugs with improved safety and efficacy profiles. For instance, in 2021, Takeda Pharmaceuticals received FDA approval for its drug Takhzyro (lanadelumab-flyo) for prophylactic treatment of HAE in patients 12 years and older.

Globally, the angioedema treatment market is expected to witness high growth in North America, Europe and Asia Pacific. Increasing access to healthcare and medical insurance coverage are some of the factors driving the adoption of angioedema therapeutics in developing economies. Key players are also focused on expanding their presence in high growth regions through strategic partnerships and joint ventures.

Market Drivers
Rising prevalence of angioedema conditions such as HAE worldwide is a major factor driving the growth of the global angioedema treatment market. According to HAE International estimates, 1 in 10,000 to 1 in 50,000 people globally are affected by HAE. Approval and launch of novel treatment options with superior clinical benefits over existing therapies is also propelling the market growth.

Market Restraints
High cost of approved drugs for angioedema treatment is one of the key challenges faced by players in this market. For instance, annual cost of treatment with C1-INH such as Cinryze and Haegarda can range from around $200,000 to $300,000. Limited awareness about rare conditions like HAE among patients and healthcare professionals also hampers the early diagnosis and management, thereby restraining the market potential.

Segment Analysis
The Angioedema Treatment market is dominated by the segment which targets hereditary angioedema. About 1 in 10,000 to 1 in 50,000 people suffer from hereditary angioedema worldwide. Due to the high incidence rate and availability of treatment options specifically meant for hereditary angioedema like C1 esterase inhibitors, plasma kallikrein inhibitor etc, this segment holds the largest share in the global angioedema treatment market.

The segment for acquired angioedema treatment is next in terms of market share. Acquired angioedema accounts for approximately 15%-20% of all angioedema cases and mostly affects middle-aged and elderly patients. Treatment includes inhibiting bradykinin receptors, complement inhibition and plasma replacement therapy.

Global Analysis
The North America region dominates the global angioedema treatment market currently due to high awareness levels regarding angioedema and availability of technologically advanced treatment options. The region is expected to continue its dominance over the forecast period as well.

However, the Asia Pacific region is projected to grow at the fastest rate during the forecast period due to increasing healthcare expenditures, growing incidences of allergies and rising awareness among the population in developing countries. Factors such as improving access to diagnosis and medications along with expanding healthcare infrastructure are expected to drive the angioedema treatment market in the Asia Pacific region.